Clinical decision support tool and rapid point-of-care platform for determining disease severity in patients with COVID-19

Michael P. McRae, Glennon W. Simmons, Nicolaos J. Christodoulides, Zhibing Lu, Stella K. Kang, David Fenyo, Timothy Alcorn, Isaac P. Dapkins, Iman Sharif, Deniz Vurmaz, Sayli S. Modak, Kritika Srinivasan, Shruti Warhadpande, Ravi Shrivastav, John T. McDevitt

Research output: Contribution to journalArticlepeer-review

Abstract

SARS-CoV-2 is the virus that causes coronavirus disease (COVID-19) which has reached pandemic levels resulting in significant morbidity and mortality affecting every inhabited continent. The large number of patients requiring intensive care threatens to overwhelm healthcare systems globally. Likewise, there is a compelling need for a COVID-19 disease severity test to prioritize care and resources for patients at elevated risk of mortality. Here, an integrated point-of-care COVID-19 Severity Score and clinical decision support system is presented using biomarker measurements of C-reactive protein (CRP), N-terminus pro B type natriuretic peptide (NT-proBNP), myoglobin (MYO), D-dimer, procalcitonin (PCT), creatine kinase-myocardial band (CK-MB), and cardiac troponin I (cTnI). The COVID-19 Severity Score combines multiplex biomarker measurements and risk factors in a statistical learning algorithm to predict mortality. The COVID-19 Severity Score was trained and evaluated using data from 160 hospitalized COVID-19 patients from Wuhan, China. Our analysis finds that COVID-19 Severity Scores were significantly higher for the group that died versus the group that was discharged with median (interquartile range) scores of 59 (40-83) and 9 (6-17), respectively, and area under the curve of 0.94 (95% CI 0.89-0.99). Although this analysis represents patients with cardiac comorbidities (hypertension), the inclusion of biomarkers from other pathophysiologies implicated in COVID-19 (e.g., D-dimer for thrombotic events, CRP for infection or inflammation, and PCT for bacterial co-infection and sepsis) may improve future predictions for a more general population. These promising initial models pave the way for a point-of-care COVID-19 Severity Score system to impact patient care after further validation with externally collected clinical data. Clinical decision support tools for COVID-19 have strong potential to empower healthcare providers to save lives by prioritizing critical care in patients at high risk for adverse outcomes.

Original languageEnglish (US)
Pages (from-to)2075-2085
Number of pages11
JournalLab on a Chip
Volume20
Issue number12
DOIs
StatePublished - Jun 21 2020

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Chemistry(all)
  • Biomedical Engineering

Fingerprint Dive into the research topics of 'Clinical decision support tool and rapid point-of-care platform for determining disease severity in patients with COVID-19'. Together they form a unique fingerprint.

Cite this